IND readiness

Vyriad Secures $25M to Advance In Vivo CAR-T VV169

Rochester, Minnesota | December 23, 2025 — Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies, announced the...

By cGxPwire Editor
December 24, 2025

.Clinical

Mondego Bio Names PTPN2 Inhibitor for First-in-Human Study

CANTANHEDE, Portugal — December 22, 2025 — Mondego Bio has announced the formal selection of ZE00-0388, a highly selective...

By cGxPwire Editor
December 23, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

IND readiness

Vyriad Secures $25M to Advance In Vivo CAR-T VV169

Mondego Bio Names PTPN2 Inhibitor for First-in-Human Study